logo
ProjectActive

Knight CNS

Sector: Manufacturing (Industrial) • Location: Latin America and the Caribbean Region

Source: International Finance Corporation (IFC)

Knight Therapeutics Inc. (Knight or the “company” - ) is a pan-American (ex-USA) specialty pharmaceutical company headquartered in Montreal, Canada that was founded in 2014 with the objective of acquiring or in-licensing innovative pharmaceutical products. In 2019, Knight acquired a controlling stake in Grupo Biotoscana (“GBT”), a specialty pharmaceutical company with a p

Status
Prospective
Sector
Manufacturing (Industrial), Government
Location
Brazil
Updated
22 Jul 2026
Source
International Finance Corporation (IFC)

ConstructChat

Ask ConstructChat about Knight CNS

Pick a question to edit it, or write your own.

First answer free · no account

I am a

Project Information FAQ

Project Information

4 Q
The project “Knight CNS” is an infrastructure initiative in the Manufacturing (Industrial) sector, located in Latin America and the Caribbean Region. Taiyo aggregates data on it from International Finance Corporation (IFC).

Participants

Sponsoring Agency

Status

Original status

active

Taiyo status

Prospective

Taiyo last update

2026-07-22

Contact

Not available for this record.

Description

Description

Knight Therapeutics Inc. (Knight or the “company” - https://www.gud-knight.com) is a pan-American (ex-USA) specialty pharmaceutical company headquartered in Montreal, Canada that was founded in 2014 with the objective of acquiring or in-licensing innovative pharmaceutical products. In 2019, Knight acquired a controlling stake in Grupo Biotoscana (“GBT”), a specialty pharmaceutical company with a presence across Latin America.  Knight completed the 100% acquisition in August 2020.   GBT owns manufacturing facilities for branded generic products in addition to a research and development center, all located in Argentina. With the GBT acquisition, Knight has expanded its operations in Latin America. The company is now directly present in 11 countries and has distributors in Central America and the Caribbean. The proposed IFC investment will be used to partially provide financing in connection with the acquisition of the rights to manufacture, market and sell Exelon® in Canada and Latin America (the “Territory”), as well as an exclusive license to use the intellectual property and the Exelon® trademark, from Novartis within the Territory (the “Exelon Acquisition”), as well as its commercialization in Canada and Latin America. Exelon® is indicated for the symptomatic treatment of mild to moderately severe dementia in people with Alzheimer’s disease and Parkinson’s disease.

Original sector

other

Location

Country

Brazil

Source

Source

International Finance Corporation (IFC)

URL

More Details

Record type

Project

Sector

Manufacturing (Industrial), Government

Article published date

2026-01-18

More on this project

Research

Free account

View all details

You are reading the public part. A free account opens the rest:

  • Every detail on this project
  • News and media coverage
  • Technical research
View all details

Free account · no card · lands you back on this project